Race Oncology (ASX:RAC) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

RAC Stoklara Genel Bakış

Klinik aşamada bir biyofarmasötik şirketi olan Race Oncology Limited, kanser hastalarının zarar verici tedaviler için karşılanmamış ihtiyaçlarını karşılamaya odaklanmaktadır.

Şirket hakkında

RAC temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 34.81% oranında artması öngörülüyor

Risk Analizi

Hissedarlar geçen yıl sulandırıldı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Anlamlı bir geliri yok ( A$4M )

Race Oncology Limited Rakipler

Aroa Biosurgery

ASX:ARX

AU$182.8m

Orthocell

ASX:OCC

AU$96.4m

Imugene

ASX:IMU

AU$357.0m

PYC Therapeutics

ASX:PYC

AU$793.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Race Oncology
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$1.69
52 Haftanın En Yüksek Seviyesi	AU$2.09
52 Haftanın En Düşük Seviyesi	AU$0.64
Beta	1.74
11 Aylık Değişim	0.60%
3 Aylık Değişim	-2.87%
1 Yıllık Değişim	98.82%
33 Yıllık Değişim	-47.35%
5 Yıllık Değişim	1,107.14%
Halka arzdan bu yana değişim	537.74%

Son Haberler & Güncellemeler

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

Aug 26

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

May 10

Recent updates

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Jun 20

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Feb 17

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 14

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Apr 01

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Apr 05

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

Mar 01

How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

Jan 07

Hissedar Getirileri

	RAC	AU Biotechs	AU Pazar
7D	-4.8%	1.5%	-0.7%
1Y	98.8%	18.3%	17.1%

Getiri vs. Endüstri: RAC geçen yıl % 18.7 oranında getiri sağlayan Australian Biotechs sektörünü aştı.

Getiri vs Piyasa: RAC geçen yıl % 17.9 oranında getiri sağlayan Australian Piyasasını aştı.

Fiyat Oynaklığı

Is RAC's price volatile compared to industry and market?
RAC volatility
RAC Average Weekly Movement	8.0%
Biotechs Industry Average Movement	10.3%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.7%

İstikrarlı Hisse Senedi Fiyatı: RAC son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: RAC 'nin haftalık oynaklığı ( 8% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2011	n/a	Daniel Tillett	www.raceoncology.com

Klinik aşamada bir biyofarmasötik şirketi olan Race Oncology Limited, kanser hastalarının zarar verici tedaviler için karşılanmamış ihtiyaçlarını karşılamaya odaklanmaktadır. Şirketin öncü ürünü, yetişkin ve pediyatrik hastalarda terapötik faydaları kanıtlanmış bir klinik geçmişe sahip küçük moleküllü bir kemoterapötik olan bisantrendir. Şirket, katı tümörlerde kardiyoproteksiyon ve gelişmiş antikanser aktivitesi sağlamak için antrasiklin kombinasyonuna klinik olarak odaklanarak çeşitli onkoloji endikasyonlarında hastaların karşılanmamış ihtiyaçlarını karşılamak için yeniden formüle edilmiş bisantreni (RC220) geliştirmektedir.

Race Oncology Limited Temel Bilgiler Özeti

Race Oncology'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
RAC temel i̇stati̇sti̇kler
Piyasa değeri	AU$288.02m
Kazançlar(TTM)	-AU$13.82m
Gelir(TTM)	AU$4.00m

71.9x

P/S Oranı

-20.8x

F/K Oranı

RAC aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
RAC gelir tablosu (TTM)
Gelir	AU$4.00m
Gelir Maliyeti	AU$2.61m
Brüt Kâr	AU$1.39m
Diğer Giderler	AU$15.21m
Kazançlar	-AU$13.82m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.081
Brüt Marj	34.72%
Net Kâr Marjı	-345.18%
Borç/Özkaynak Oranı	0%

RAC uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

RAC Stoklara Genel Bakış

Ödüller

Risk Analizi

Race Oncology Limited Rakipler

ASX:ARX

AU$182.8m

ASX:OCC

AU$96.4m

ASX:IMU

AU$357.0m

ASX:PYC

AU$793.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Consensus revenue estimates increase by 12%

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

Price target increased by 26% to AU$3.22

New minor risk - Share price stability

New minor risk - Shareholder dilution

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

Recent updates

Consensus revenue estimates increase by 12%

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

Price target increased by 26% to AU$3.22

New minor risk - Share price stability

New minor risk - Shareholder dilution

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

New major risk - Financial position

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer

Race Oncology Limited, Annual General Meeting, Nov 27, 2023

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

New minor risk - Share price stability

New minor risk - Financial data availability

Race Oncology Limited Announces Board Changes

New minor risk - Market cap size

Race Oncology Limited Announces Board Changes

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Race Oncology Limited Appoints Damian Clarke-Bruce as Director

Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer Trial

Race Oncology Limited, Annual General Meeting, Feb 21, 2023

Board Member recently bought AU$50k worth of stock

Board Member recently bought AU$99k worth of stock

Race Oncology Limited Appoints Damian Clarke-Bruce as Managing Director, Effective 1 February 2023

Race Oncology Limited Announces It Has Submitted A Human Ethics Application to Hunter New England Human Research Ethics Committee Seeking Approval to Commence the Observational Stage of A Planned Phase 1/2B Clinical Trial of Zantrene

Race Oncology Limited Appoints Daniel (Danny) Sharp as an Independent Non-Executive Director

Race Oncology Limited Receives Positive Guidance on Zantrene Via Pre-IND Meeting with US FDA

High number of new and inexperienced directors

Race Oncology Ltd Announces Management Changes

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited, Annual General Meeting, Nov 24, 2022

Race Oncology Limited Develops Improved Iv Formulation of Zantrene

Race Oncology Limited Initiates New Drug Discovery Program

Board Member recently bought AU$165k worth of stock

Race Oncology Limited Shares Further Interim Results from Preclinical Cardioprotection Program in Collaboration with Researchers from the University of Newcastle

Race Oncology Limited Announces Interim Results from its Preclinical Melanoma Research Program

Race Oncology Limited Expands FTO Targeting Phase 1b/2a Extramedullary AML & MDS Trial to Europe

Race Oncology Limited Announces the Dose Escalation Phase 1b Stage of the Relapsed or Refractory Acute Myeloid Leukaemia (R/R AML) Trial Running At the Chaim Sheba Medical Centre, Israel

Race Oncology Limited Appoints Guy Breitenbucher to Its Scientific Advisory Board

Race Oncology Limited Receives Governance Approval for AML EMD & MDS Trial

High number of new and inexperienced directors

Race Oncology Limited Receives Human Ethics Approval for Its Open Label Clinical Trial of Zantrene in Patients with Extramedullary Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited Announces Preclinical & Clinical Programs Update

Board Member recently bought AU$56k worth of stock

Race Oncology Limited Announces MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene

Race Oncology Limited Appoints Christina Manfre as Chief Financial Officer

Non-Independent Non-Executive Chairman recently sold AU$995k worth of stock

Board Member recently bought AU$59k worth of stock

Insider recently sold AU$4.4m worth of stock

Race Oncology Limited Announces Interim Results from the Zantrene® Preclinical Heart Safety Research Program Led by Eminent Cardiotoxicity Researchers, Associate Professors Aaron Sverdlov and Doan Ngo

Non-Independent Non-Executive Chairman exercised options to buy AU$9.8m worth of stock.

Non-Independent Non-Executive Chairman recently bought AU$710k worth of stock

Non-Executive Chairman recently sold AU$193k worth of stock

Non-Executive Chairman exercised options to buy AU$5.7m worth of stock.

Insider recently sold AU$4.3m worth of stock

Race Oncology Limited Executes Contract to Commence Phase 1b/2 AML Trial at Chaim Sheba Israel